Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody

Código QR

Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody

Abstract Immune-oncology (IO) drug therapy is effective against various types of cancer. Although several, potential, clinical predictive markers have been identified, none so far have proven reliable. Herein we evaluated changes in serum alanine aminotransferase (ALT), which is upregulated by the a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeshi Azuma, Takumi Takeuchi, Yukihide Matayoshi, Shin Namiki, Tetsuya Obara, Kazuhiro Imamura, Mikio Takamori
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2a6f8c097636447083d21605efcde241
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Alanine aminotransferase controls seed dormancy in barley
por: Kazuhiro Sato, et al.
Publicado: (2016)

Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure
por: Daichi Maeda, et al.
Publicado: (2021)

THROMBOCYTOPENIA AND ELEVATED ALANINE AMINOTRANSFERASE LEVELS IN MALARIA PATIENTS
por: Sayed Tanveer Abbas Gilani, et al.
Publicado: (2021)

The Association of Aspartate Aminotransferase/Alanine Aminotransferase Ratio with Diabetic Nephropathy in Patients with Type 2 Diabetes
por: Xu J, et al.
Publicado: (2021)

Role of Vaginal Fluid Aspartate Aminotransferase and Alanine Aminotransferase in the Diagnosis of Pre-Labor Rupture of Membranes
por: Aya Elnemr, et al.
Publicado: (2021)

The Relationship Between Aspartate Aminotransferase To Alanine Aminotransferase Ratio And Metabolic Syndrome In Adolescents In Northeast China
por: Lin S, et al.
Publicado: (2019)

Role of alanine aminotransferase in determining the biliary etiology in acute pancreatitis
por: Shailesh Simkhada, et al.
Publicado: (2016)

High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients
por: Cheng Qin, et al.
Publicado: (2020)

Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population.
por: Ming-Hua Zheng, et al.
Publicado: (2012)

Alanine aminotransferase and risk of the metabolic syndrome: a linear dose-response relationship.
por: Setor K Kunutsor, et al.
Publicado: (2014)

Low alanine aminotransferase as a risk factor for chronic obstructive pulmonary disease in males
por: Yong Jun Choi, et al.
Publicado: (2021)

Influence of study model, baseline catalytic concentrations and analytical system on the stability of serum alanine aminotransferase
por: Bauça Josep Miquel, et al.
Publicado: (2020)

Association Between Aspartate Aminotransferase to Alanine Aminotransferase Ratio and Incidence of Type 2 Diabetes Mellitus in the Japanese Population: A Secondary Analysis of a Retrospective Cohort Study
por: Chen L, et al.
Publicado: (2021)

Impact of elevated aspartate and alanine aminotransferase on metabolic syndrome and its components among adult people living in Ningxia, China
por: Kun-Peng He, et al.
Publicado: (2015)

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
por: Chan-Young Ock, et al.
Publicado: (2017)

Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase
por: Jiyuan Zhou, et al.
Publicado: (2017)

Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteers.
por: Anja Kittel, et al.
Publicado: (2014)

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
por: W Joost Lesterhuis, et al.
Publicado: (2013)

Joint Effect of Hepatic Steatosis and Alanine Aminotransferase Within the Normal Range on Incident Ischemic Heart Disease: A Prospective Study in Koreans
por: Jung DH, et al.
Publicado: (2021)

The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.
por: Benjamin A H Jensen, et al.
Publicado: (2013)

Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
por: Zhiyong Wang, et al.
Publicado: (2019)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi R, et al.
Publicado: (2020)

Considering serum alanine aminotransferase and gamma-glutamyltransferase levels together strengthen the prediction of impaired fasting glucose risk: a cross-sectional and longitudinal study
por: Ji Hye Jeong, et al.
Publicado: (2021)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
por: I. O. Chikileva, et al.
Publicado: (2019)

Author Correction: Considering serum alanine aminotransferase and gamma-glutamyltransferase levels together strengthen the prediction of impaired fasting glucose risk: a cross-sectional and longitudinal study
por: Ji Hye Jeong, et al.
Publicado: (2021)

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma
por: Ying Mei, et al.
Publicado: (2021)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Maohua Li, et al.
Publicado: (2021)

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
por: Yoshihisa Shimada, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017)

Absence of CD28-CTLA4-PD-L1 Costimulatory Molecules Reduces Herpes Simplex Virus 1 Reactivation
por: Harry H. Matundan, et al.
Publicado: (2021)

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xin Xie, et al.
Publicado: (2022)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh L, et al.
Publicado: (2018)

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
por: Rajasekharan Somasundaram, et al.
Publicado: (2021)

Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles
por: Zhaohan Wei, et al.
Publicado: (2021)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Florie Bertrand, et al.
Publicado: (2017)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).
por: Shinkichi Takamori, et al.
Publicado: (2021)

Virological failure and associated factors among children receiving anti-retroviral therapy, Northwest Ethiopia.
por: Biruk Bayleyegn, et al.
Publicado: (2021)

Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports
por: Mihaylova Z., et al.
Publicado: (2019)

Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
por: Wen Shi Lee, et al.
Publicado: (2021)